Use of Alpelisib for Patients with PIK3CA-mutated advanced Breast Cancer

被引：0
|
作者：
Malter, Wolfram [1 ]
Alakus, Hakan [2 ]
Mallmann, Peter [1 ]
Bruns, Christiane [2 ]
机构：
[1] Univ Cologne, Uniklin Koln, Klin & Poliklin Frauenheilkunde & Geburtshilfe, Cologne, Germany
[2] Univ Cologne, Uniklin Koln AoR, Klin & Poliklin Allgemein Viszeral & Tumorchirurg, Kerpener Str 62, D-50937 Cologne, Germany
来源：
ONKOLOGE | 2019年 / 25卷 / 08期
关键词：
D O I：
10.1007/s00761-019-0619-9
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：724 / 725
页数：2
相关论文
共 50 条
  • [31] FDA Approves Inavolisib Combo for PIK3CA-Mutated, HR plus Breast Cancer
    Zhang, Jinwei
    CURRENT MEDICINAL CHEMISTRY, 2025,
  • [32] Regular aspirin (ASA) use and survival in patients with PIK3CA-mutated metastatic colorectal cancer (CRC)
    Kothari, Nishi
    Kim, Richard D.
    Gibbs, Peter
    Yeatman, Timothy Joseph
    Schell, Michael J.
    Desai, Jayesh
    Tie, Jeanne
    Lipton, Lara Rachel
    Jorissen, Robert N.
    Wong, Hui-Li
    Sieber, Oliver
    Day, Fiona
    Faragher, Ian
    Jones, Ian
    Ben Tran
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (03)
  • [33] SEQUence of Endocrine therapy in advanced Luminal Breast cancer (SEQUEL-Breast): A phase 2 study on fulvestrant beyond progression in combination with alpelisib for PIK3CA-mutated, HR+HER2-advanced breast cancer
    Almekinders, Cornelia Am
    Konings, Inge Rhm
    van der Noort, Vincent
    van den Berg, Susan M.
    Bos, Monique Emm
    Dezentje, Vincent O.
    CANCER RESEARCH, 2023, 83 (05)
  • [34] Correction: Alpelisib and fulvestrant in PIK3CA-mutated hormone receptor-positive HER2-negative advanced breast cancer included in the French early access program
    D. Bello Roufai
    A. Gonçalves
    T. De La Motte Rouge
    S. Akla
    C. Blonz
    J. Grenier
    J. Gligorov
    M. Saghatchian
    C. Bailleux
    H. Simon
    I. Desmoulins
    Z. Tharin
    E. Renaud
    M. Bertho
    M-A Benderra
    S. Delaloge
    L. Robert
    P. Cottu
    J. Y. Pierga
    D. Loirat
    A. Bertucci
    B. Renouf
    F. C. Bidard
    F. Lerebours
    Oncogene, 2023, 42 : 1417 - 1417
  • [35] The association between baseline patient characteristics and alpelisib-induced hyperglycaemia in patients with HR+, HER2-, PIK3CA-mutated metastatic breast cancer
    Godina, Eva
    Borstnar, Simona
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [36] Alpelisib Plus Letrozole Shows Promise After CDK 4/6 Inhibitor Therapy in PIK3CA-Mutated HR+/HER2-Advanced Breast Cancer
    不详
    ONCOLOGIST, 2021, 26 : S15 - S16
  • [37] Descriptive profile of PIK3CA-mutated colorectal cancer in postmenopausal women
    Amanda I. Phipps
    Karen W. Makar
    Polly A. Newcomb
    International Journal of Colorectal Disease, 2013, 28 : 1637 - 1642
  • [38] Exceptional Response to Copanlisib in a Heavily Pretreated Patient With PIK3CA-Mutated Metastatic Breast Cancer
    Spathas, Nikolaos
    Economopoulou, Panagiota
    Kotsantis, Ioannis
    Oikonomopoulos, Nikolaos
    Psyrri, Amanda
    JCO PRECISION ONCOLOGY, 2020, 4 : 335 - 340
  • [39] The way to precision medicine in gynecologic cancers: The first case report of an exceptional response to alpelisib in a PIK3CA-mutated endometrial cancer
    Passarelli, Anna
    Ventriglia, Jole
    Pisano, Carmela
    Cecere, Sabrina Chiara
    Di Napoli, Marilena
    Rossetti, Sabrina
    Tambaro, Rosa
    Tarotto, Luca
    Fiore, Francesco
    Farolfi, Alberto
    Bartoletti, Michele
    Pignata, Sandro
    FRONTIERS IN ONCOLOGY, 2023, 12
  • [40] The role of BYL719 in PIK3CA-mutated cervical cancer
    Bogani, G.
    Bini, M.
    Raspagliesi, F.
    ANNALS OF ONCOLOGY, 2022, 33 : S389 - S389
12345